1. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial. Issue 3 (March 2023) Authors: Madhi, Shabir A; Kwatra, Gaurav; Richardson, Simone I; Koen, Anthonet L; Baillie, Vicky; Cutland, Clare L; Fairlie, Lee; Padayachee, Sherman D; Dheda, Keertan; Barnabas, Shaun L; Bhorat, Qasim Ebrahim; Briner, Carmen; Ahmed, Khatija; Aley, Parvinder K; Bhikha, Sutika; Bhorat, A E; Esmail, Aliasga... Journal: Lancet infectious diseases Issue: Volume 23:Issue 3(2023) Page Start: 295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Issue 9 (September 2021) Authors: Madhi, Shabir A; Koen, Anthonet L; Izu, Alane; Fairlie, Lee; Cutland, Clare L; Baillie, Vicky; Padayachee, Sherman D; Dheda, Keertan; Barnabas, Shaun L; Bhorat, Qasim Ebrahim; Briner, Carmen; Aley, Parvinder K; Bhikha, Sutika; Hermanus, Tandile; Horne, Elizea; Jose, Aylin; Kgagudi, Prudence; Lamb... Journal: Lancet Issue: Volume 8:Issue 9(2021) Page Start: e568 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗